Drug intelligence / Profile preview

pulean

Development stage: Unknown
Lead developer: Hefei Huafang Pharmaceutical Technology
Modality: Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

Pulean is a Traditional Chinese Medicine (TCM) product primarily composed of *Brassica campestris* L. (rape) pollen. It is widely used in China for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH). The drug is formulated as tablets and is known for its anti-inflammatory properties and its ability to improve urinary symptoms associated with prostate enlargement. It works by reducing edema and congestion in the prostate gland, thereby alleviating symptoms like frequent urination, urgency, and painful urination.

Brand names: Pulean普乐安
Other names: Pulean Tablets普乐安片Rape Pollen TabletsBrassica campestris pollen

Beyond the preview

Go deeper on pulean.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pulean.

Explore the full profile